Medical Economics, May 9, 2024: House Small Business Committee hearing focused on when government regulations undermine medical innovation and services but also agreed on the need to ensure safe and effective medical products.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA Brings Lab Tests Under Its Oversight
MedPage Today, April 29, 2024: FDA issues the final rule for lab-developed tests (LDTs) and we explain that the rule has a giant deadly loophole allowing thousands of diagnostic tests and genetic tests for cancer and other deadly diseases to be sold without evidence they are accurate.
Read More »Feds declare turf, rubber playgrounds “generally safe’
Politico E&E NEWS, April 18, 2024: EPA released its 2024 report on artificial turf, which says it contains dangerous chemicals but that the exposures are “generally safe.’ NCHR’s Dr. Diana Zuckerman asks what does that mean? If it is generally safe that means it isn’t safe for everyone, but EPA doesn’t explain how many will be harmed and doesn’t explain what is known and not known. It’s not credible.
Read More »Americans Are Paying Billions to Take Drugs That Don’t Work
April 15, 2024 By Robert Langreth, Fiona Rutherford and Tanaz Meghjani One ALS drug made $400 million in sales for its maker. It doesn’t work. A cancer treatment brought in $500 million. That one turned out to have no effect on survival. A blood cancer medication made nearly $850 million before being withdrawn for two […]
Read More »10 doctors on FDA panel for Abbott heart device had financial ties to the company. The FDA didn’t disclose the payments.
NBC News and Kaiser Health News, April 6, 2024: NBC News reported the Kaiser Health News investigation showing that 10 doctors who advised FDA about Abbott’s heart device TriClip had financial ties to the company that weren’t disclosed. Their votes almost unanimously supported approval. We explain that FDA conflict of interest rules are too loose.
Read More »